ATE310955T1 - Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten - Google Patents

Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten

Info

Publication number
ATE310955T1
ATE310955T1 AT02256808T AT02256808T ATE310955T1 AT E310955 T1 ATE310955 T1 AT E310955T1 AT 02256808 T AT02256808 T AT 02256808T AT 02256808 T AT02256808 T AT 02256808T AT E310955 T1 ATE310955 T1 AT E310955T1
Authority
AT
Austria
Prior art keywords
chemokine receptor
topology
detecting
compositions
methods
Prior art date
Application number
AT02256808T
Other languages
English (en)
Inventor
Jennifer M Burns
Zhenhua Miao
Zheng Wei
Maureen C Howard
Brett A Premack
Thomas J Schall
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of ATE310955T1 publication Critical patent/ATE310955T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02256808T 2001-11-30 2002-09-30 Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten ATE310955T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33810001P 2001-11-30 2001-11-30
US10/245,850 US7442512B2 (en) 2001-11-30 2002-09-16 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Publications (1)

Publication Number Publication Date
ATE310955T1 true ATE310955T1 (de) 2005-12-15

Family

ID=26937511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02256808T ATE310955T1 (de) 2001-11-30 2002-09-30 Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten

Country Status (10)

Country Link
US (1) US7442512B2 (de)
EP (2) EP1316801B1 (de)
JP (1) JP4485204B2 (de)
KR (1) KR100961237B1 (de)
AT (1) ATE310955T1 (de)
AU (1) AU2002351213B2 (de)
CA (1) CA2468407A1 (de)
DE (1) DE60207514T2 (de)
DK (1) DK1316801T3 (de)
WO (1) WO2003047420A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1365245A1 (de) * 2002-05-23 2003-11-26 Bayer Aktiengesellschaft Diagnostika und Therapeutika von mit Chemokine Rezeptor 11 (CCR11) assoziierten Krankheiten
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
PL1691837T3 (pl) * 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
EP1723970A4 (de) * 2004-03-09 2009-08-12 Univ Kyoto Medizinische zusammensetzung mit cxcr3-hemmer
CN100357738C (zh) * 2004-03-26 2007-12-26 博奥生物有限公司 一种检测小分子化合物的方法
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
WO2007124414A2 (en) 2006-04-21 2007-11-01 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
GB0614755D0 (en) * 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
MX2009003306A (es) * 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
EP2522754B1 (de) * 2007-08-13 2014-04-02 Baxter International Inc. IVIg-Modulation von Chemokinen zur Behandlung von Multipler Sklerose, Morbus Alzheimer und Morbus Parkinson
WO2009029885A1 (en) * 2007-08-31 2009-03-05 Massachusetts Institute Of Technology Treatment of autoimmune disease
EP2285833B1 (de) * 2008-05-16 2014-12-17 Ablynx N.V. Gegen cxcr4 und andere gpcr gerichtete aminosäuresequenzen sowie verbindungen damit
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
AU2011328246B2 (en) * 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
SG191716A1 (en) 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
KR101359317B1 (ko) * 2011-08-23 2014-02-10 건양대학교산학협력단 Ｄ6 디코이 수용체의 세포 외 도메인 1을 포함하는 항암용 약학 조성물
NZ629828A (en) 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
EP2682187B1 (de) * 2012-07-02 2017-09-13 Molecular Devices, LLC Auswahlverfahren und -vorrichtung
US9718887B2 (en) 2012-09-06 2017-08-01 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating metastatic cancer
CN105408355A (zh) 2013-01-31 2016-03-16 瓦克纳斯有限公司 用于提高免疫球蛋白a水平的方法
ES2776243T3 (es) 2015-06-03 2020-07-29 Medical College Wisconsin Inc Un polipéptido de dímero CCL20 bloqueado modificado por ingeniería
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
CN107810420B (zh) * 2015-06-25 2020-08-14 豪夫迈·罗氏有限公司 用于测定抗体或配体结合和功能的基于细胞的测定
CN110022897A (zh) 2016-09-26 2019-07-16 Ｍｐｏ株式会社 卵子、受精卵或胚胎的质量改善剂
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN107312092B (zh) * 2017-05-04 2020-12-11 华南农业大学 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用
CN113684238A (zh) * 2021-08-09 2021-11-23 广州医科大学附属第一医院（广州呼吸中心） Cxc趋化因子受体3作为咳嗽药物靶点的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US6537764B1 (en) * 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
AU734090B2 (en) 1996-09-10 2001-06-07 Millennium Pharmaceuticals, Inc. CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use
US5876946A (en) * 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
EP0897980A3 (de) 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: Eine menschliche Spleissvariante des CXCR4 Chemokinrezeptors
US6306653B1 (en) * 1998-01-20 2001-10-23 Codon Diagnostics, Llc Detection and treatment of breast disease
ES2156581T5 (es) 1998-03-30 2015-01-21 Northwest Biotherapeutics, Inc. Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6449054B1 (en) * 1998-08-01 2002-09-10 Canon Kabushiki Kaisha Dynamic assignment of group addresses for controlling parallel peripheral devices
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6365356B1 (en) * 1999-03-17 2002-04-02 Cornell Research Foundation, Inc. Receptors that regulate cell signaling relating to chemokines
US6448054B1 (en) 1999-04-08 2002-09-10 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US20020061599A1 (en) * 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
EP1263791A4 (de) * 2000-02-09 2004-07-07 Human Genome Sciences Inc Menschlicher g-protein chemokinrezeptor hdgnr10 (ccr5 rezeptor)
US20020064770A1 (en) * 2000-03-21 2002-05-30 Nestor John J. Binding compounds and methods for identifying binding compounds
US20020025536A1 (en) * 2000-06-26 2002-02-28 Jeno Gyuris Methods and reagents for isolating biologically active antibodies

Also Published As

Publication number Publication date
CA2468407A1 (en) 2003-06-12
US7442512B2 (en) 2008-10-28
AU2002351213B2 (en) 2008-01-03
KR100961237B1 (ko) 2010-06-03
US20030124628A1 (en) 2003-07-03
EP1316801B1 (de) 2005-11-23
JP4485204B2 (ja) 2010-06-16
AU2002351213B8 (en) 2003-06-17
AU2002351213A1 (en) 2003-06-17
WO2003047420A3 (en) 2004-02-26
KR20040099258A (ko) 2004-11-26
EP1316801A1 (de) 2003-06-04
JP2005527189A (ja) 2005-09-15
DE60207514T2 (de) 2006-08-10
EP1461061A4 (de) 2005-08-31
DK1316801T3 (da) 2006-03-06
WO2003047420A2 (en) 2003-06-12
DE60207514D1 (de) 2005-12-29
EP1461061A2 (de) 2004-09-29

Similar Documents

Publication Publication Date Title
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
EP1351707A4 (de) Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
ATE424560T1 (de) Marker für neuromyelitis optica
ATE540319T1 (de) Verfahren für die bestimmung von fk506
EP1578371A4 (de) Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
EP1572091A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
DE69609161D1 (de) Amplifikationsoligonukleotide und sonden für borrelia, die mit lyme kranheit assoziiert sind
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
ATE347698T1 (de) Verfahren zum nachweis von alzheimer-krankheit
DE50007635D1 (de) Verfahren zur diagnose von sjögren-syndrom
WO2004083241A3 (en) Btc-interacting proteins and use thereof
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
DE60126991D1 (de) Verfahren ZUR DIAGNOSE VON SCHIZOPHRENIE
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands
WO2005037231A3 (en) Methods of detecting and treating facioscapulohumeral muscular dystrophy
ATE253223T1 (de) Verfahren und materialien zur diagnose instabiler angina
ATE360094T1 (de) Tcf-1 nukleotidsequenzvariation
WO2002075317A3 (en) Screening for drugs against disorders associated with schizophrenia

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties